164 related articles for article (PubMed ID: 38582787)
1. RevCAR-expressing immune effector cells for targeting of Fn14-positive glioblastoma.
Saleh HA; Mitwasi N; R Loureiro L; Kegler A; Soto KEG; Hoffmann L; Crespo E; Arndt C; Bergmann R; Bachmann M; Feldmann A
Cancer Gene Ther; 2024 Apr; ():. PubMed ID: 38582787
[TBL] [Abstract][Full Text] [Related]
2. Specific and safe targeting of glioblastoma using switchable and logic-gated RevCAR T cells.
Saleh HA; Mitwasi N; Ullrich M; Kubeil M; Toussaint M; Deuther-Conrad W; Neuber C; Arndt C; R Loureiro L; Kegler A; González Soto KE; Belter B; Rössig C; Pietzsch J; Frenz M; Bachmann M; Feldmann A
Front Immunol; 2023; 14():1166169. PubMed ID: 37122703
[TBL] [Abstract][Full Text] [Related]
3. Targeting colorectal cancer cells using AND-gated adaptor RevCAR T-cells.
Soto KEG; Loureiro LR; Bartsch T; Arndt C; Kegler A; Mitwasi N; Drewitz L; Hoffmann L; Saleh HA; Crespo E; Mehnert M; Daglar C; Abken H; Momburg F; Bachmann M; Feldmann A
Front Immunol; 2023; 14():1302354. PubMed ID: 38169746
[TBL] [Abstract][Full Text] [Related]
4. Targeting Acute Myeloid Leukemia Using the RevCAR Platform: A Programmable, Switchable and Combinatorial Strategy.
Kittel-Boselli E; Soto KEG; Loureiro LR; Hoffmann A; Bergmann R; Arndt C; Koristka S; Mitwasi N; Kegler A; Bartsch T; Berndt N; Altmann H; Fasslrinner F; Bornhäuser M; Bachmann MP; Feldmann A
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638268
[TBL] [Abstract][Full Text] [Related]
5. Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy.
Feldmann A; Hoffmann A; Bergmann R; Koristka S; Berndt N; Arndt C; Rodrigues Loureiro L; Kittel-Boselli E; Mitwasi N; Kegler A; Lamprecht C; González Soto KE; Bachmann M
Oncoimmunology; 2020 Jul; 9(1):1785608. PubMed ID: 32923149
[TBL] [Abstract][Full Text] [Related]
6. Fn14-targeted BiTE and CAR-T cells demonstrate potent preclinical activity against glioblastoma.
Li G; Zhang Z; Cai L; Tang X; Huang J; Yu L; Wang G; Zhong K; Cao Y; Liu C; Wang Y; Tong A; Zhou L
Oncoimmunology; 2021; 10(1):1983306. PubMed ID: 34595061
[TBL] [Abstract][Full Text] [Related]
7. Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival.
Genßler S; Burger MC; Zhang C; Oelsner S; Mildenberger I; Wagner M; Steinbach JP; Wels WS
Oncoimmunology; 2016 Apr; 5(4):e1119354. PubMed ID: 27141401
[TBL] [Abstract][Full Text] [Related]
8. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen receptor T cells targeting cell surface GRP78 efficiently kill glioblastoma and cancer stem cells.
Wang S; Wei W; Yuan Y; Sun B; Yang D; Liu N; Zhao X
J Transl Med; 2023 Jul; 21(1):493. PubMed ID: 37481592
[TBL] [Abstract][Full Text] [Related]
10. An Oncolytic Virus Expressing IL15/IL15Rα Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma.
Ma R; Lu T; Li Z; Teng KY; Mansour AG; Yu M; Tian L; Xu B; Ma S; Zhang J; Barr T; Peng Y; Caligiuri MA; Yu J
Cancer Res; 2021 Jul; 81(13):3635-3648. PubMed ID: 34006525
[TBL] [Abstract][Full Text] [Related]
11. IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM.
Zannikou M; Duffy JT; Levine RN; Seblani M; Liu Q; Presser A; Arrieta VA; Chen CJ; Sonabend AM; Horbinski CM; Lee-Chang C; Miska J; Lesniak MS; Gottschalk S; Balyasnikova IV
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36759014
[TBL] [Abstract][Full Text] [Related]
12. Minimizing the non-specific binding of nanoparticles to the brain enables active targeting of Fn14-positive glioblastoma cells.
Schneider CS; Perez JG; Cheng E; Zhang C; Mastorakos P; Hanes J; Winkles JA; Woodworth GF; Kim AJ
Biomaterials; 2015 Feb; 42():42-51. PubMed ID: 25542792
[TBL] [Abstract][Full Text] [Related]
13. Dual Targeting of Glioblastoma Cells with Bispecific Killer Cell Engagers Directed to EGFR and ErbB2 (HER2) Facilitates Effective Elimination by NKG2D-CAR-Engineered NK Cells.
Kiefer A; Prüfer M; Röder J; Pfeifer Serrahima J; Bodden M; Kühnel I; Oberoi P; Wels WS
Cells; 2024 Jan; 13(3):. PubMed ID: 38334638
[TBL] [Abstract][Full Text] [Related]
14. "UniCAR"-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells.
Mitwasi N; Feldmann A; Arndt C; Koristka S; Berndt N; Jureczek J; Loureiro LR; Bergmann R; Máthé D; Hegedüs N; Kovács T; Zhang C; Oberoi P; Jäger E; Seliger B; Rössig C; Temme A; Eitler J; Tonn T; Schmitz M; Hassel JC; Jäger D; Wels WS; Bachmann M
Sci Rep; 2020 Feb; 10(1):2141. PubMed ID: 32034289
[TBL] [Abstract][Full Text] [Related]
15. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
16. Natural killer cell immunotherapy in glioblastoma.
Hosseinalizadeh H; Habibi Roudkenar M; Mohammadi Roushandeh A; Kuwahara Y; Tomita K; Sato T
Discov Oncol; 2022 Oct; 13(1):113. PubMed ID: 36305981
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of the third generation EphA2 CAR-T cells against glioblastoma is associated with interferon gamma induced PD-L1.
An Z; Hu Y; Bai Y; Zhang C; Xu C; Kang X; Yang S; Li W; Zhong X
Oncoimmunology; 2021; 10(1):1960728. PubMed ID: 34408922
[TBL] [Abstract][Full Text] [Related]
18. Turning the tables on cytomegalovirus: targeting viral Fc receptors by CARs containing mutated CH2-CH3 IgG spacer domains.
Proff J; Brey CU; Ensser A; Holter W; Lehner M
J Transl Med; 2018 Feb; 16(1):26. PubMed ID: 29422056
[TBL] [Abstract][Full Text] [Related]
19. Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival.
Poli A; Wang J; Domingues O; Planagumà J; Yan T; Rygh CB; Skaftnesmo KO; Thorsen F; McCormack E; Hentges F; Pedersen PH; Zimmer J; Enger PØ; Chekenya M
Oncotarget; 2013 Sep; 4(9):1527-46. PubMed ID: 24127551
[TBL] [Abstract][Full Text] [Related]
20. Targeting of the alpha
Cobb DA; de Rossi J; Liu L; An E; Lee DW
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35210306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
